Atai Beckley NV Q3 FY2021 earnings call

Florian Brand introduced the strategy of advancing innovative pipeline focused on mental health disorders. Srini Rao reviewed pipeline updates including COMPASS Pathways' Phase 2b positive data for COMP360, Perception Neuroscience's Phase 2a trial of PCN-101, Recognify's Phase 2a biomarker study of RL-007, GABA therapeutics' Phase 1 trial of GRX-917, DemeRx IB's Phase 1/2a trial of DMX-1002, and EntheogeniX's work on novel psychedelic compounds. Florian also mentioned the launch of ATAI Impact philanthropic program

Cash and equivalents totaled $430.3 million as of September 30, 2021, compared to $453.6 million as of June 30, 2021. Third quarter 2021 total operating expenses were $33.6 million vs. $61.3 million in Q2, with decreases in non-cash stock based compensation offset by increases in R&D and G&A expenses excluding stock based compensation

Cash runway expected to fund operations into 2024. Anticipate top-line data for Recognify’s Phase 2a by end of 2021 and GABA Phase 1 data in early 2022. Remain active in business developments

Risks described in SEC filings including risks related to forward-looking statements, drug development uncertainties, and market risks

Q: Questions on various programs like RL-007, COMP360, Perception Neuroscience's PCN-101, GABA's GRX-917, etc.

A: Responses from Srinivas Rao, Florian Brand, Greg Weaver addressing details such as trial designs, timelines, biomarker findings, PK, and business development implications